BMO Capital analyst Brennan Hawken raised the firm’s price target on Houlihan Lokey (HLI) to $211 from $209 and keeps an Outperform rating on the shares. The company’s revenue beat was driven by RX, though partially offset by marginal misses in corporate finance and FVA, or Financial and Valuation Advisory, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLI:
- Houlihan Lokey price target lowered to $214 from $218 at Keefe Bruyette
- Houlihan Lokey reports Q3 adjusted EPS $1.94, consensus $1.87
- HLI Upcoming Earnings Report: What to Expect?
- Houlihan Lokey acquires Audere Partners, Mellum Capital real estate business
- Houlihan Lokey price target lowered to $218 from $228 at Keefe Bruyette